Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise A. Olsen, Sean Whittaker, Eric C. Vonderheid et al.|Blood|2007Cited by 1.4k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Sean Whittaker et al.|Journal of Clinical Oncology|2011Cited by 657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Tatyana Feldman et al.|The Lancet|2017Cited by 580
Defining early mycosis fungoidesNicola Pimpinelli, Gary S. Wood, Elise A. Olsen et al.|Journal of the American Academy of Dermatology|2005Cited by 543
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017Franz Trautinger, Robert Knobler, Johanna Eder et al.|European Journal of Cancer|2017Cited by 449